Shogo Nakamoto

Shogo Nakamoto

Auto-generated profile, based on publicly available information

Shogo Nakamoto

Division of Breast and Thyroid Gland Surgery, Fukuyama City Hospital, Hiroshima, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SNShogo Nakamoto
Shogo Nakamoto
MIMasahiko Ikeda
Masahiko Ikeda
SKShinichiro Kubo
Shinichiro Kubo
MYMari Yamamoto
Mari Yamamoto
TYTetsumasa Yamashita
Tetsumasa Yamashita
ANAkifumi Notsu
Akifumi Notsu
Although paclitaxel plus bevacizumab (PB) therapy is an effective chemotherapeutic regimen for HER2-negative advanced breast cancer (ABC), predictive markers for its effectiveness remain undefined. We investigated the usefulness of systemic immunity markers associated with lymphocytes as predictive markers for PB therapy in patients with HER2-negative ABC. We retrospectively reviewed data from 114 patients with HER2-negative ABC who underwent PB therapy from November 2011 to December 2019. We calculated the absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) as representative systemic immunity markers. The time to treatment failure (TTF) and overall survival (OS) of the patients with high ALC, low NLR, and high LMR were significantly longer compared with those of the patients with low ALC, high NLR, and low LMR. A multivariable analysis revealed that high ALC, low NLR, and low PLR were independent predictors for TTF and high ALC, low NLR, and high LMR were independent predictors for OS. Systemic immunity markers were significantly associated with longer TTF and OS in patients who underwent PB therapy and may represent predictive markers for PB therapy in patients with HER2-negative ABC.

3 June 2021 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
SNShogo Nakamoto
Shogo Nakamoto
MIMasahiko Ikeda
Masahiko Ikeda
SKShinichiro Kubo
Shinichiro Kubo
MYMari Yamamoto
Mari Yamamoto
TYTetsumasa Yamashita
Tetsumasa Yamashita
Background/Aim: We investigated the usefulness of dynamic changes in absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio (NLR) during eribulin therapy as predictive markers for survival benefit including post-progression survival (PPS). Patients and Methods: We retrospectively investigated 94 advanced breast cancer (ABC) patients who underwent eribulin therapy between July 2011 and June 2020. Results: The multivariate analysis showed that high baseline ALC and low NLR were independent predictive markers for overall survival (OS) (p=0.007 and p=0.011, respectively) and PPS (p=0.005 and p=0.007, respectively). Dynamic changes in ALC were also associated with OS and PPS (p=0.015, and p=0.026, respectively) and were an independent predictive marker for PPS (p=0.021). Conclusion: Baseline ALC and NLR and dynamic changes in ALC during eribulin therapy were significantly associated with survival benefit including PPS for patients with ABC.

8 May 2021 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
JWJunichiro Watanabe
Junichiro Watanabe
KMKoichi Mitsuya
Koichi Mitsuya
SNShogo Nakamoto
Shogo Nakamoto
HHHideyuki Harada
Hideyuki Harada
SDShoichi Deguchi
Shoichi Deguchi
YNYoko Nakasu
Yoko Nakasu

30 April 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SNShogo Nakamoto
Shogo Nakamoto
Tadahiko ShienTadahiko Shien
Tadahiko Shien
TITakayuki Iwamoto
Takayuki Iwamoto
SKShinichiro Kubo
Shinichiro Kubo
MYMari Yamamoto
Mari Yamamoto
MIMasahiko Ikeda
Masahiko Ikeda
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) are the standard agents for treating patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer (ER + HER2 − ABC). However, markers predicting the outcomes of CDK4/6i treatment have yet to be identified. This study was a single-center retrospective cohort study. We retrospectively evaluated 101 patients with ER + HER2 − ABC receiving CDK4/6i in combination with endocrine therapy at Fukuyama City Hospital between November 2017 and July 2021. We investigated the clinical outcomes and the safety of CDK4/6i treatment, and the absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio (NLR) as predictive markers for CDK4/6i. We defined the cut-off values as 1000/μL for ALC and 3 for NLR, and divided into “low” and “high” groups, respectively. We evaluated 43 and 58 patients who received abemaciclib and palbociclib, respectively. Patients with high ALC and low NLR had significantly longer overall survival than those with low ALC and high NLR (high vs. low; ALC: HR 0.29; 95% CI 0.12–0.70; NLR: HR 2.94; 95% CI 1.21–7.13). There was no significant difference in efficacy between abemaciclib and palbociclib and both had good safety profiles. We demonstrated that ALC and NLR might predict the outcomes of CDK4/6i treatment in patients with ER + HER2 − ABC.

30 October 2023 in Clinical and Experimental Medicine
Verified
Journal Article
Closed access
PDF file
SNShogo Nakamoto
Shogo Nakamoto
TSTadahiko Shien
Tadahiko Shien
MIMitsuya Itoh
Mitsuya Itoh
YYYutaka Yamamoto
Yutaka Yamamoto
SOShozo Ohsumi
Shozo Ohsumi
MIMasahiko Ikeda
Masahiko Ikeda

29 April 2020 in In Vivo
Verified
Journal Article
Open access
PDF file
SNShogo Nakamoto
Shogo Nakamoto
JWJunichiro Watanabe
Junichiro Watanabe
SOShoichiro Ohtani
Shoichiro Ohtani
SMSatoshi Morita
Satoshi Morita
MIMasahiko Ikeda
Masahiko Ikeda
Background: The efficacy of paclitaxel and bevacizumab (PB) compared with other chemotherapies in patients with human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer is unclear. Patients and Methods: We retrospectively investigated 301 patients with HER2− ABC who received first-line chemotherapy from January 2011 to December 2016. Results: We included 114 patients who received PB and 187 patients who received other chemotherapies. After propensity score matching, the PB group showed a significantly superior overall response rate (77.8% vs. 38.9%, p<0.0001) and median time to treatment failure (7.3 vs. 5.9 months, p=0.035). In subgroup analyses, PB improved the median overall survival of patients with pleural lesions or pulmonary lymphangiopathy (not reached vs. 18.9 months, p=0.037), and of patients with three or more metastatic sites without liver metastases, (48.0 vs. 27.3 months, p=0.015). Conclusion: Compared with conventional chemotherapy, PB improved the overall response rate and time to treatment failure in patients with HER2− advanced breast cancer and improved overall survival in some patient subgroups.